Site Search

Early stage researchers, life science entrepreneurs, and companies are encouraged to apply starting May 2

The purpose of the Screening Improvement Program mechanism is to catalyze efforts aimed at improving the screening system used for early diagnosis. 

The Cystic Fibrosis Foundation is requesting applications with a Letter of Intent for innovative, multi-site quality improvement projects that aim to test tools and processes facilitating remote cystic fibrosis care delivery. 

The patient-centered outcomes research (PCOR) training manual provides discrete steps, tools, and resources that CF Center research teams can take to integrate and maintain patient/caregiver-partners in CF research.

This program is intended to facilitate research that will contribute to the development of new therapies or therapeutic strategies to treat cystic fibrosis with an emphasis on advancing CFTR gene repair and replacement approaches.
 

The Cystic Fibrosis Foundation is requesting letters of intent for research projects that aim to use available clinical trials in organ transplantation specimens and/or clinical data to improve knowledge of chronic lung allograft dysfunction pathogenesis and explore new approaches to detection, prevention, monitoring, or treatment of chronic lung allograft dysfunction.
 

The Therapeutics Development Network Coordinating Center partners with the Investigational Drug Service at Seattle Children's Hospital to provide pharmacy-related support for multi-center CF clinical studies.

The strength of the Therapeutics Development Network Coordinating Center lies in our unparalleled experience in setting up and managing cystic fibrosis studies and our intimate knowledge of the CF research community.

To address the unique and emerging needs of people with cystic fibrosis, the Cystic Fibrosis Foundation has established a research working group to identify knowledge gaps, determine research priorities, and develop the infrastructure needed to conduct the research related to sexual, reproductive, and gender health.

The Clinical Research Executive Committee (CREC) assesses how a specific protocol fits within the overall clinical research priorities of the cystic fibrosis community and assigns it a rating.